[1] Mazzaferri EL.  An Overview of the Management of Papillary and Follicular Thyroid Carcinoma[J]. Thyroid, 1999, 9(5): 421-427.   doi: 10.1089/thy.1999.9.421
[2] Chen WQ, Zheng RS, Baade PD, et al.  Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.   doi: 10.3322/caac.21338
[3]

Forman D, Ferlay J. The global and regional burden of cancer[M]//Stewart BW, Wild CP. World Cancer Report. Lyon: IARCPress, 2014: 16−53.
[4] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[5] Chung JK, Cheon GJ.  Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology[J]. Endocrinol Metab (Seoul), 2014, 29(3): 233-239.   doi: 10.3803/EnM.2014.29.3.233
[6] Pacini F, Basolo F, Bellantone R, et al.  Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies[J]. J Endocrinol Invest, 2018, 41(7): 849-876.   doi: 10.1007/s40618-018-0884-2
[7] Samuels MH.  Psychiatric and cognitive manifestations of hypothyroidism[J]. Curr Opin Endocrinol Diabetes Obes, 2014, 21(5): 377-383.   doi: 10.1097/MED.0000000000000089
[8] Kannan L, Shaw PA, Morley MP, et al.  Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes[J]. Circ Heart Fail, 2018, 11(12): e005266-.   doi: 10.1161/CIRCHEARTFAILURE.118.005266
[9] Cho YY, Kim SK, Jung JH, et al.  Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin[J]. Endocrine, 2019, 64(2): 293-298.   doi: 10.1007/s12020-018-1807-x
[10] Beukhof CM, Massolt ET, Visser TJ, et al.  Effects of Thyrotropin on Peripheral Thyroid Hormone Metabolism and Serum Lipids[J]. Thyroid, 2018, 28(2): 168-174.   doi: 10.1089/thy.2017.0330
[11] Bano A, Chaker L, Mattace-Raso FUS, et al.  Thyroid Function and the Risk of Atherosclerotic Cardiovascular Morbidity and Mortality: The Rotterdam Study[J]. Circ Res, 2017, 121(12): 1392-1400.   doi: 10.1161/CIRCRESAHA.117.311603
[12]

Leng O, Razvi S. Hypothyroidism in the older population[J/OL]. Thyroid Res, 2019, 12: 2[2019-03-03]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367787. DOI: 10.1186/s13044-019-0063-3.
[13] Lee J, Yun MJ, Nam KH, et al.  Quality of Life and Effectiveness Comparisons of Thyroxine Withdrawal, Triiodothyronine Withdrawal, and Recombinant Thyroid-Stimulating Hormone Administration for Low-Dose Radioiodine Remnant Ablation of Differentiated Thyroid Carcinoma[J]. Thyroid, 2010, 20(2): 173-179.   doi: 10.1089/thy.2009.0187
[14] Liepe K.  Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using 131I-whole body scans to identify metastases of differentiated thyroid cancer[J]. Int J Surg, 2015, 16: 107-112.   doi: 10.1016/j.ijsu.2015.02.016
[15] Arpaia D, Ippolito S, Peirce C, et al.  Importance of recombinant human thyrotropin as an adjuvant in the radioiodine treatment of thyroid cancer[J]. Expert Rev Endocrinol Metab, 2017, 12(4): 261-267.   doi: 10.1080/17446651.2017.1338945
[16] Rosario PW, Mourão GF, Calsolari MR.  Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b)[J]. Arch Endocrinol Metab, 2017, 61(2): 167-172.   doi: 10.1590/2359-3997000000247
[17] Borget I, Bonastre J, Catargi B, et al.  Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase Ⅲ ESTIMABL Trial[J]. J Clin Oncol, 2015, 33(26): 2885-2892.   doi: 10.1200/JCO.2015.61.6722
[18] Klein I, Ojamaa K.  Thyroid hormone and the cardiovascular system[J]. N Engl J Med, 2001, 344(7): 501-509.   doi: 10.1056/NEJM200102153440707
[19] Jabbar A, Pingitore A, Pearce SHS, et al.  Thyroid hormones and cardiovascular disease[J]. Nat Rev Cardiol, 2017, 14(1): 39-55.   doi: 10.1038/nrcardio.2016.174
[20] Hoftijzer HC, Bax JJ, Heemstra KA, et al.  Short-term overt hypothyroidism induces discrete diastolic dysfunction in patients treated for differentiated thyroid carcinoma[J]. Eur J Clin Invest, 2009, 39(3): 204-210.   doi: 10.1111/j.1365-2362.2009.02088.x
[21] Gazdag A, Nagy EV, Erdei A, et al.  Aortic stiffness and left ventricular function in patients with differentiated thyroid cancer[J]. J Endocrinol Invest, 2015, 38(2): 133-142.   doi: 10.1007/s40618-014-0143-0
[22] An JH, Song KH, Kim DL, et al.  Effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer[J]. J Int Med Res, 2017, 45(1): 38-50.   doi: 10.1177/0300060516664242
[23] Robbins RJ, Driedger A, Magner J.  Recombinant Human Thyrotropin-Assisted Radioiodine Therapy for Patients with Metastatic Thyroid Cancer Who Could Not Elevate Endogenous Thyrotropin or Be Withdrawn from Thyroxine[J]. Thyroid, 2006, 16(11): 1121-1130.   doi: 10.1089/thy.2006.16.1121
[24] Dardano A, Monzani F.  Recombinant human TSH acutely impairs endothelium-dependent vasodilation[J]. Eur J Endocrinol, 2007, 157(3): 367-.   doi: 10.1530/EJE-07-0345
[25] Desideri G, Bocale R, Milardi D, et al.  Enhanced proatherogenic inflammation after recombinant human TSH administration in patients monitored for thyroid cancer remnant[J]. Clin Endocrinol (Oxf), 2009, 71(3): 429-433.   doi: 10.1111/j.1365-2265.2008.03485.x
[26] Ippolito S, Ippolito R, Peirce C, et al.  Recombinant Human Thyrotropin Improves Endothelial Coronary Flow Reserve in Thyroidectomized Patients with Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(11): 1528-1534.   doi: 10.1089/thy.2016.0082
[27]

Saif A, Mousa S, Assem M, et al. Endothelial dysfunction and the risk of atherosclerosis in overt and subclinical hypothyroidism [J/OL]. Endocr Connect, 2018, 7(10): 1075−1080[2019-03-03]. https://www.ncbi.nlm.nih.gov/pmc/acticles/PMC6198186. DOI: 10.1530/EC-18-0194.
[28] Sigal GA, Tavoni TM, Silva BMO, et al.  Effects of Short-Term Hypothyroidism on the Lipid Transfer to High-Density Lipoprotein and Other Parameters Related to Lipoprotein Metabolism in Patients Submitted to Thyroidectomy for Thyroid Cancer[J]. Thyroid, 2019, 29(1): 53-58.   doi: 10.1089/thy.2018.0190
[29] Jung KY, Ahn HY, Han SK, et al.  Association between thyroid function and lipid profiles, apolipoproteins, and high-density lipoprotein function[J]. J Clin Lipidol, 2017, 11(6): 1347-1353.   doi: 10.1016/j.jacl.2017.08.015
[30] Villabona C, Sahun M, Roca M, et al.  Blood volumes and renal function in overt and subclinical primary hypothyroidism[J]. Am J Med Sci, 1999, 318(4): 277-280.   doi: 10.1097/00000441-199910000-00007
[31] Bulur O, Dal K, Ertugrul DT, et al.  Renal function improves with the treatment of hypothyroidism[J]. Endocr Res, 2017, 42(3): 246-251.   doi: 10.1080/07435800.2017.1293686
[32] Coura-Filho GB, Willegaignon J, Buchpiguel CA, et al.  Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer[J]. Thyroid, 2015, 25(12): 1291-1296.   doi: 10.1089/thy.2015.0173
[33] Duranton F, Lacoste A, Faurous P, et al.  Exogenous thyrotropin improves renal function in euthyroid patients, while serum creatinine levels are increased in hypothyroidism[J]. Clin Kidney J, 2013, 6(5): 478-483.   doi: 10.1093/ckj/sft092
[34] Smith CD, Grondin R, LeMaster W, et al.  Reversible Cognitive, Motor, and Driving Impairments in Severe Hypothyroidism[J]. Thyroid, 2015, 25(1): 28-36.   doi: 10.1089/thy.2014.0371
[35] Jeong HS, Choi EK, Song IU, et al.  Differences in Brain Glucose Metabolism During Preparation for 131I Ablation in Thyroid Cancer Patients: Thyroid Hormone Withdrawal Versus Recombinant Human Thyrotropin[J]. Thyroid, 2017, 27(1): 23-28.   doi: 10.1089/thy.2016.0293
[36] Shin YW, Choi YM, Kim HS, et al.  Diminished Quality of Life and Increased Brain Functional Connectivity in Patients with Hypothyroidism After Total Thyroidectomy[J]. Thyroid, 2016, 26(5): 641-649.   doi: 10.1089/thy.2015.0452
[37] Cooke GE, Mullally S, Correia N, et al.  Hippocampal Volume Is Decreased in Adults with Hypothyroidism[J]. Thyroid, 2014, 24(3): 433-440.   doi: 10.1089/thy.2013.0058
[38] Bottomley A.  The cancer patient and quality of life[J]. Oncologist, 2002, 7(2): 120-125.   doi: 10.1634/theoncologist.7-2-120
[39] Rubic M, Kuna SK, Tesic V, et al.  The most common factors influencing on quality of life of thyroid cancer patients after thyroid hormone withdrawal[J]. Psychiatr Danub, 2014, 26(Suppl 3): S520-527.
[40] Taïeb D, Sebag F, Cherenko M, et al.  Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study[J]. Clin Endocrinol (Oxf), 2009, 71(1): 115-123.   doi: 10.1111/j.1365-2265.2008.03424.x
[41] Piccardo A, Puntoni M, Ferrarazzo G, et al.  Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?[J]. Eur J Nucl Med Mol Imaging, 2018, 45(7): 1218-1223.   doi: 10.1007/s00259-018-3955-x